Interim Report Q3 2019

Summary

Financial overview July 1 – September 30, 2019

  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 189.8 M (loss: 94.0)
  • Loss per share, before and after dilution, was SEK 3.53 (loss: 2.14)
  • On September 30 cash and cash equivalents amounted to SEK 1,122.3 M (488.9)

Significant events during the period July 1 – September 30, 2019

  • In late August it was announced that Klaas Bakker, MD, PhD, was appointed as Chief Medical Officer and assumed his duties in early November
  • In mid-September new interim data in RRMM patients with extramedullary disease (EMD) from the pivotal Phase 2 HORIZON trial were presented at the International Myeloma Workshop
  • At the end of September, it was announced that the patient recruitment in the pivotal Phase 2 HORIZON trial had been completed

Financial overview of the group

SEK thousand 2019
Jul – Sep
20181)
Jul – Sep
2019
Jan – Sep
20181)
Jan – Sep
20181)
Jan – Dec
Net sales
Operating loss -189,597 -94,051 -495,148 -299,104 -410,963
Loss before tax -189,710 -94,051 -495,520 -299,104 -410,965
Loss for the period -189,780 -94,051 -495,801 -299,104 -411,112
Earnings per share before and
after dilution (SEK)
-3.53 -2.14 -9.90 -7.03 -9.58
Cash flow from operating activities -207,774 -94,265 -473,592 -224,872 -333,727
Cash and cash equivalents
at the end of the period
1,122,297 488,869 1,122,297 488,869 375,617
Research & development costs/
Operating expenses %
80% 73% 79% 75% 76%

1) Earlier periods have been adjusted to reflect correction of errors, see note 7.

Conference call for investors, analysts and the media

The Interim Report Q3 2019 and an operational update will be presented by CEO Jakob Lindberg and members of Oncopeptides management team, Tuesday November 19, 2019 at 13:30 (CET). The conference call will also be streamed via a link on the website: www.oncopeptides.com.

Phone numbers for participants from:
Sweden: +46 8 505 583 59
Europe: +44 3333 009 034
USA: +1 833 823 05 89

Financial calendar

Year-end Report 2019: February 20, 2020
Interim Report Q1, 2020: May 26, 2020
Annual General Meeting May 26, 2020

For further information

Jakob Lindberg, CEO, Oncopeptides AB
E-mail: jakob.lindberg@oncopeptides.com
Telephone: +46 (0)8 615 20 40

Rein Piir, Head of Investor Relations, Oncopeptides AB
E-mail: rein.piir@oncopeptides.com
Telephone: +46 (0)70 853 72 92

This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on November 19, 2019.

About Oncopeptides

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being tested in multiple clinical trials including the pivotal Phase 2 HORIZON trial and the ongoing Phase 3 OCEAN trial. Oncopeptides’ headquarters is in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.